Trending Articles

article thumbnail

The Respiratory Disease Trifecta: What to Know About COVID-19, Flu, and RSV

Drug Topics

In order to provide the best care, it’s crucial that pharmacists stay up-to-date on the latest guidance and data for flu, COVID-19, and RSV—even when that information is constantly changing.

200
200
article thumbnail

CDC advisory panel says people 65 and older should get a Covid spring booster shot

STAT

An expert panel advising the Centers for Disease Control and Prevention on vaccines on Wednesday recommended that people 65 and older should get an additional Covid-19 vaccine shot this spring. The recommendation was approved by CDC Director Mandy Cohen, allowing the United States to join Canada and the United Kingdom in offering a spring booster this year to people at high risk of severe disease if they contract Covid.

Vaccines 145
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Hyperbaric Oxygen Therapy May Be the First, Only Clinically Effective Treatment for Long COVID

Pharmacy Times

“I’m better than I was before I had long COVID, and in so many ways,” said a patient in an interview with Pharmacy Times.

181
181
article thumbnail

ViVE 2024: Health systems are making big bets on AI. Here's how

Fierce Healthcare

LOS ANGELES — AI took center stage at the ViVE 2024 conference this week and health systems across the country are deploying the tech to tackle issues from easing the drudgery of medical docum | AI took center stage at the ViVE 2024 conference this week and health systems across the country are deploying the tech to tackle issues from easing the drudgery of medical documentation to making it easier for patients to get information about their medical care.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

AstraZeneca finally drops roxadustat US rights after FDA rejection, trial failure

Fierce Pharma

AstraZeneca and FibroGen have finally reached the end of the road for their U.S. collaboration on the oral anemia drug roxadustat. | More than two years after a high-profile FDA rejection, AstraZeneca has backed out of a collaboration with FibroGen for the latter’s oral anemia drug roxadustat in the U.S. Still, AZ left the partners' China pact intact.

FDA 120
article thumbnail

OTC Colon Cancer Screening Test Now Available in Pharmacies Across US

Drug Topics

Reese Pharmaceutical’s ColoTest has a suggested retail price of $19.99 and will also be sold on major retail shelves later this spring.

201
201

More Trending

article thumbnail

Pharmacy Focus: Limited Series - Celebrity Endorsements in Pharmaceuticals

Pharmacy Times

The podcast highlights addressing misinformation, the impact of celebrity endorsements in pharmaceuticals, and the important role of pharmacists in educating patients.

128
128
article thumbnail

Abridge clinches $150M to build out generative AI for medical documentation

Fierce Healthcare

Investors continue to pour money into generative AI startups and Abridge is riding this wave as it rapidly scales its technology across U.S. health systems. | Along with the funding round, Abridge also announced an enterprise agreement with Connecticut-based Yale New Haven Health System to give thousands of clinicians access to its AI-powered clinical documentation technology.

article thumbnail

Perrigo plots hundreds of job cuts as it embarks on restructuring initiative

Fierce Pharma

Over-the-counter self-care specialist Perrigo is poised to leave hundreds of workers by the wayside as it embarks on the next leg of its corporate journey. | As part of a cost-cutting and restructuring initiative dubbed "Project Energize," Perrigo expects to trim roughly 6% of its total staff, the company said in a fourth-quarter earnings release Tuesday.

124
124
article thumbnail

Lecanemab-irmb Approved for Alzheimer Disease

Drug Topics

On January 6, 2023, the FDA granted lecanemab-irmb (Leqembi) accelerated approval for treating mild cognitive impairment and mild dementia in patients with Alzheimer disease.

FDA 182
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

STAT+: White House to hold a listening session on reforming pharmacy benefit managers

STAT

In a bid to combat prescription drug costs, the White House will hold a listening session on Monday in search of ways to reform pharmacy benefit managers , according to people familiar with the plans. The list of attendees includes representatives from the federal government and industry, who are expected to provide insights into how the largest pharmacy benefit managers determine which medicines are covered by insurers and employers, as well as prices that are paid at pharmacy counters.

Insurance 144
article thumbnail

Gepotidacin Demonstrates Non-Inferiority Treating Uncomplicated Urogenital Gonorrhea in Phase 3 Trial

Pharmacy Times

Gepotidacin was compared with the combination of ceftriaxone and azithromycin in adolescent and adult patients with uncomplicated urogenital gonorrhea.

138
138
article thumbnail

WSJ: Department of Justice conducting antitrust probe of UnitedHealth Group

Fierce Healthcare

Amid a tense week for UnitedHealth Group as the company continues to navigate a cyberattack against its Optum unit, the Wall Street Journal reports that the Biden administration is quietly launchin | Amid a tense week for UnitedHealth Group as the company continues to navigate a cyberattack against its Optum unit, the Wall Street Journal reports that the Biden administration is quietly launching an antitrust probe into the company.

117
117
article thumbnail

FDA says yes to Allecra, no to Venatorx UTI drugs

pharmaphorum

The FDA has approved Allecra Therapeutics' Exblifep, a combination antibiotic for complicated urinary tract infections (cUTIs) that will now launch later this year, but turned down a rival product from Venatorx.

FDA 114
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Breakthrough Vaccine for Chronic Hepatitis B Enters First In-Human Trial

Drug Topics

With over 3% of the world’s population affected by chronic hepatitis B, TherVacB has the potential to address a critical unmet need for a cure.

Vaccines 200
article thumbnail

Opinion: Medicare Advantage is bad for patients and bad for investors

STAT

In 2023, enrollment in Medicare Advantage, the version of Medicare run by private insurers, surpassed 50% of eligible beneficiaries for the very first time. Going by this headline, or perhaps the predictable flood of advertisements for plans during the fall’s open enrollment period, you might be fooled into thinking 2023 was MA’s best year yet.

Insurance 144
article thumbnail

Data From OUtMATCH Study Show Benefits of Xolair for Common Food Allergies

Pharmacy Times

The data follow the FDA approval of omalizumab for the reduction of allergic reactions, including anaphylaxis, that can occur after exposure to 1 or more foods.

FDA 131
article thumbnail

'Podnosis': Maternal mental health in the spotlight

Fierce Healthcare

This week on “Podnosis,” we explore the critical issue of maternal mental health. | This week on "Podnosis," Editor-in-Chief Ayla Ellison explores the critical issue of maternal mental health in an interview with Dr. Ken Levey, co-founder and CEO of Mother Goose Health.

109
109
article thumbnail

Janux plans $200m offer on back of prostate cancer readout

pharmaphorum

Buoyed by data from a trial of its T-cell engager (TCE) therapy in prostate cancer that almost tripled its share price, Janux Therapeutics has moved quickly to file a stock offering that could add around $200 million to its cash position. The San Diego biotech is offering $175 million in a public offering that could rise to $201.5 million if underwriters take up an option, less discounts and commissions.

106
106
article thumbnail

Repeat Dosing Study Demonstrates Positive Data for Neffy Epinephrine Nasal Spray

Drug Topics

Manufacturer ARS Pharma will submit the data as part of a response to a CRL received in 2023.

232
232
article thumbnail

STAT+: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

STAT

One by one, the companies behind Zoloft, Prozac, and Paxil soured on psychiatry. It was the early 2000s, and as America warmed to the sounds of Sisqó and Shakira, the world’s largest pharmaceutical firms were running out of ideas to treat mental illness. Their blockbuster treatments for depression and schizophrenia had reshaped society and made billions of dollars in the process, but the old cash cows were soon to go generic.

Insurance 139
article thumbnail

Expert Predicts Psychedelics Will Be Integrated into Current Regimens for Treating Mental Health Diseases

Pharmacy Times

Investigators continue to conduct regulated and controlled clinical trials to build compelling, high-quality evidence on their therapeutic potential.

137
137
article thumbnail

Optum's Change Healthcare responding to 'cybersecurity issue'

Fierce Healthcare

Change Healthcare is mitigating a "cybersecurity issue" that began Wednesday, and details remain scant. | Change Healthcare is mitigating a "cybersecurity issue" that began Wednesday, and details remain scant.

131
131
article thumbnail

GSK antibiotic gepotidacin clears phase 3 gonorrhoea trial

pharmaphorum

GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea.

115
115
article thumbnail

Digital Health Tools Could Increase PrEP Uptake Among Young Individuals At-Risk For HIV

Drug Topics

Participants of a recent study who received automated text messaging and monitoring, as well as peer support and coaching, increased PrEP uptake from 11% to over 20%.

159
159
article thumbnail

Q&A: The scientific integrity sleuth taking on the widespread problem of research misconduct

STAT

Elisabeth Bik, a microbiologist by training, has become one of the world’s most influential science detectives. An authority on scientific image analysis who’s been profiled in The New Yorker for her unique ability to spot duplicated or doctored photographs, she appeared frequently in the news over the past year as one of the experts who raised research misconduct concerns that led to an investigation into, and the eventual departure of, former Stanford president Marc Tessier-Lavig

136
136
article thumbnail

FDA Approves Expanded Indication for Bikatarvy for HIV Treatment

Pharmacy Times

The new indication includes individuals with HIV who have suppressed viral loads with known or suspected M184V/I resistance.

FDA 149
article thumbnail

ViVE 2024: Simple HealthKit launches new kidney disease testing program

Fierce Healthcare

LOS ANGELES — Simple HealthKit is launching a new kidney care program that aims to support health plans in driving better outcomes. | LOS ANGELES — Simple HealthKit is launching a new kidney care program that aims to support health plans in driving better outcomes.

117
117
article thumbnail

Amgen boots up Ohio 'smart facility' where it plans to employ 400—and a trio of robots, too

Fierce Pharma

Amgen is now open for business in Central Ohio after cutting the ribbon at its “most advanced facility to date.” | Amgen is now open for business in Central Ohio after cutting the ribbon at its “most advanced facility to date.” Dubbed “Amgen Ohio,” the nearly 300,000-square-foot biomanufacturing plant in New Albany, Ohio, is set to employ 400 full-time employees and leverage the “latest innovation and technology.

109
109
article thumbnail

Sanofi trumpets win for oral BTK drug in chronic hives

pharmaphorum

Sanofi gets a win for its oral BTK inhibitor rilzabrutinib in chronic hive disorder CSU, setting up a phase 3 programme as it chases after Novartis’ remibrutinib in this indication.

115
115
article thumbnail

STAT+: FTC says pharmacy benefit managers are stonewalling requests for information

STAT

A much-anticipated inquiry by U.S. antitrust regulators into pharmaceutical industry middlemen has been stymied because the companies have failed to provide many of the documents that, in some cases, were requested as far back as June 2022. The inquiry was begun by the Federal Trade Commission in response to the role that pharmacy benefit managers play in the cost of prescription medicines.

article thumbnail

All Pharmacies Are Not the Same: Community Pharmacy Quality

Pharmacy Times

Patients and other stakeholders need to be able to compare pharmacies based on standardized, transparent metrics with a measurement system to make informed decisions.

article thumbnail

Beacon Therapeutics unveils promising interim results for gene therapy AGTC-501

Pharmaceutical Technology

AGTC-501 is in Phase II development for retinitis in the SKYLINE trial (NCT03316560) and addresses unmet needs within the retinitis space

114
114
article thumbnail

To BioMarin CEO Alexander Hardy, hemophilia A gene therapy Roctavian needs 3 stars to align

Fierce Pharma

Even Alexander Hardy, the former Genentech leader who managed the blockbuster hemophilia drug Hemlibra, can’t immediately bend the laggard launch trajectory of BioMarin’s gene therapy Roctavian.

121
121